Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. (MMED.NE) Company Profile & Overview
Explore Mind Medicine (MindMed) Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Mind Medicine (MindMed) Inc. (MMED.NE) Company Profile & Overview
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.